⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29703099 | 0.79 | — | — | |
| SCHEMBL753511 | 0.79 | — | — | |
| SCHEMBL29518741 | 0.75 | — | — | |
| SCHEMBL3717170 | 0.75 | — | — | |
| SCHEMBL16860535 | 0.75 | — | — | |
| SCHEMBL5700383 | 0.69 | NPC1 (0.37) | — | |
| SCHEMBL7669080 | 0.69 | — | — | |
| SCHEMBL2425486 | 0.68 | — | — | |
| SCHEMBL5642817 | 0.68 | — | — | |
| SCHEMBL351727 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021104256-A1 | HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 杭州华东医药集团新药研究院有限公司 | 2021-06-03 | — | — | WO | disclosed |
| WO-2021057975-A1 | MUTANT IDH2 INHIBITOR AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| US-10160695-B2 | Synthesis of meta-substituted [18F]-3-fluoro-4-aminopyridines by direct radiofluorination of pyridine N-oxides | THE UNIVERSITY OF CHICAGO (US) | 2018-12-25 | — | — | US | disclosed |
| US-20170355648-A1 | SYNTHESIS OF META-SUBSTITUTED [18F]-3-FLUORO-4-AMINOPYRIDINES BY DIRECT RADIOFLUORINATION OF PYRIDINE N-OXIDES | THE UNIVERSITY OF CHICAGO | 2017-12-14 | — | — | US | disclosed |
| US-20170355648-A1 | SYNTHESIS OF META-SUBSTITUTED [18F]-3-FLUORO-4-AMINOPYRIDINES BY DIRECT RADIOFLUORINATION OF PYRIDINE N-OXIDES | THE UNIVERSITY OF CHICAGO | 2017-12-14 | — | — | US | disclosed |
| EP-2176250-B1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS CH (CH) | 2011-10-26 | — | — | EP | disclosed |
| WO-2011047315-A1 | SUBSITITUTED BENZIMIDAZOLES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-09-30 | — | — | US | disclosed |
| CN-101801950-A | Heteroaryl piperidine derivative as the modified replacement of melanocortin-4 receptor | SANTHERA PHARMACEUTICALS CH | 2010-08-11 | — | — | CN | disclosed |
| EP-2210885-A1 | Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010081666-A1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-07-22 | — | — | WO | disclosed |
| EP-2176250-A1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-04-21 | — | — | EP | disclosed |
| EP-2019100-A1 | Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| WO-2009010299-A1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-01-22 | — | — | WO | disclosed |